1 not yet recruiting, 1 recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow BG-C9074: new trials by email Literature Review of BG-C9074 trials Research Report on BG-C9074
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors BG-C9074, Tislelizumab, Bevacizumab - Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 308 | 2024-04-12 | 2026-09-16 |
Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1)
BeOne Medicines (2)
Australia (1) · Brazil (1) · China (1) · Japan (1) · United States (1)